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Macrophages are pivotal for the regulation of immune and inflammatory responses, but whether their role in HIV infection is protective or deleterious
remains unclear. In this study, we investigated the effect of pro- and anti-inflammatory stimuli on macrophage sensitivity to two different aspects of HIV
infection: their susceptibility to infection stricto sensu, which we measured by endpoint titration method, and their ability to support virus spread, which we
measured by using an RT activity assay in infection kinetics. We show a partially protective role for pro-inflammatory agents as well as for IL-4. We also
illustrate that various different stimuli display differential effects on macrophage susceptibility to HIVand on virus replication that occurs thereafter. On the
other hand, HIVreplication strongly repressedCD206 andCD163 expression, thus clearly orientatingmacrophages towards a pro-inflammatory phenotype,
but independently of TNF. Taken together, our results emphasize that HIV infection of macrophages sets up inflammation at the cell level but through
unexpected mechanisms. This may limit target susceptibility and participate in virus clearance but may also result in tissue damage.
© 2006 Elsevier Inc. All rights reserved.Keywords: Inflammation; Macrophage; Activation; HIV; Cytokine; ChemokineIntroduction
Cells of the monocyte/macrophage lineage are among the first
that are infected by HIV. They disseminate the virus and serve as
ubiquitous virus reservoir during infection (Connor and Ho, 1994;
Gartner et al., 1986; Igarashi et al., 2001; Schuitemaker et al., 1992).
Depending on their tissue distribution, macrophages constitute
distinct cell populations differentially involved in a variety of
immunoregulatory, phagocytic, and secretory functions (Seljelid
and Eskeland, 1993), with major differences in their regulation of⁎ Corresponding author. Laboratoire de Neuro-Immuno-Virologie CEA, DSV/
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doi:10.1016/j.virol.2006.02.031inflammatory and immune responses. For example, alveolar and
placental macrophages suppress T cell response and exhibit anti-
inflammatory properties, as opposed to the classical pro-inflam-
matory properties of activated macrophages. Despite the central
implication of macrophage activation in the course of AIDS, the
relative capacities of pro- and anti-inflammatory macrophages to
serve as reservoirs or to spread virus have not been thoroughly
studied to date. For example, macrophages are productively
infected in the central nervous system, and their microenvironment
may exhibit pro-inflammatory features as a result of the production
of pro-inflammatory cytokines (for review, see Kaul et al., 2001)
but also anti-inflammatory properties in the vicinity of apoptotic
cells (De Simone et al., 2004; Fadok et al., 1998). On the other
hand, the cytokine/chemokine network regulates both inflammation
and HIV replication (for review, see Fantuzzi et al., 2003), but the
Fig. 1. Effect of pro- and anti-inflammatory stimulations on macrophage
infectability. HumanMDMwere treated for 3 days with the different stimuli. (A)
Effect on CD4 and CCR5 quantitative expression. Results are expressed as
means ± standard deviations for 3 independent experiments. (B) Susceptibility
of differentially activated macrophages. Stimulated macrophages were assessed
for their susceptibility to HIV infection by using an endpoint dilution titration
method. Results are expressed as means ± standard deviations for 3 independent
experiments.
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characterized and remain the subject of debate. Indeed some studies
showed an increase in TNF-α production by HIV-1 or gp120
(Karsten et al., 1996; Lee et al., 2005; Mabondzo et al., 1991),
whereas Valentin et al. (1992) reported an increase in IL-1α and IL-
1β but not in TNF-α after the infection of blood-derived
macrophages. Similar discrepancies have been reported for IL-10.
Studies performed by Gessani et al. (1997), Akridge et al. (1994),
and Yoo et al. (1996) showed an increase in IL-10 as a result of
infection, whereas Bergamini et al. (1998) did not. Thus, the effect
of HIV infection on the production of both TNF-α and IL-10 (i.e.,
on macrophages status regarding inflammatory equilibrium)
remains unclear. It is thus uncertain whether the inflammatory
face of HIV infection originates from direct effects at the cellular
level or whether it requires organization at the tissue level to express
itself. In this regard, the quantitative expression of the membrane
markers of alternative macrophage activation (for review (Goerdt
and Orfanos, 1999), CD163 (Hogger et al., 1998), and CD206
(Stein et al., 1992), may help in better understanding how HIV
affects macrophage activation. Indeed, these receptors exhibit
increased antigenic density on alternatively activated, anti-
inflammatory macrophages, while they are repressed in the context
of pro-inflammatory activation (Buechler et al., 2000; Cowan et al.,
1992; DeFife et al., 1997; Goerdt and Orfanos, 1999; Goerdt et al.,
1999; Gordon, 1998; Porcheray et al., 2005; Schaer et al., 2002;
Shepherd et al., 1994; Sulahian et al., 2000; Van den Heuvel et al.,
1999; Williams et al., 2002), allowing a direct analysis of
macrophage activation balance.
We thus investigated the relationship between inflammation
and HIV infection/replication in macrophages. We focussed on
two key questions we consider critical: (i) what are the direct
effects of HIV infection on macrophage functions? And (ii) how
do changes in macrophage activation influence their ability to
be infected and to support viral replication? To this end, we first
evaluated whether differential macrophage activation in-
fluenced their susceptibility to HIV entry and the establishment
of a productive infection. This was evaluated by an endpoint
dilution titration that measures the minimum amount of virus
that can productively infect the cells. We then assessed the
intensity of viral replication in infected macrophages, by using a
classical RT activity assay throughout replication kinetics, as an
indicator of virus production and spread capacity. We know
from previous studies that a stimulating molecule may have
opposite effects on the pre- and post-integration steps of the
HIV cycle (Bailer et al., 2000; Finnegan et al., 1996; Kedzierska
et al., 2003; Lane et al., 1999). Accordingly, we also studied the
ability of activated macrophages to support sustained virus
expression. We then determined the consequences of HIV
replication on the expression of alternative versus classical
macrophage activation markers and compared this with the
expression of other previously studied markers such as
cytokines and chemokines.
This study, performed in a unique model of human
monocyte-derived macrophages (MDM) using a wide panel
of pro- and anti-inflammatory mediators, shows that macro-
phage activation pathways mostly exert partial inhibitory effects
on HIV, regardless of their pro- or anti-inflammatory charac-teristics. Nevertheless, HIV replication, in turn, induces a clear
and rapid switch towards a pro-inflammatory phenotype but
through TNF-α- and IL-1β-independent mechanisms that
remain to be elucidated.
Results
Effect of pro- and anti-inflammatory stimulations on
macrophage susceptibility to HIV infection
We first determined the expression levels of CD4 and
CCR5 that may account for cell susceptibility to HIV-1/Ba-L
(Fig. 1A). Control expression levels were 87,500 ± 16,800 and
12,300 ± 3500 MEF, for CD4 and CCR5 respectively
(mean ± SEM, n = 5). Due to interindividual variations in
antigenic density, results are hereafter expressed as a percentage
of untreated cell expression level. Almost all tested stimulations
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CSF, IL-4, IFN-γ, TNF-α, and LPS even led to an almost
complete abolishment of CCR5 detection. On the other hand,
IL-10 upregulated both CD4 and CCR5 membrane expression
levels, whereas M-CSF had no effect. CD4 and CCR5
expression closely paralleled each other (r = 0.907), confirming
their co-expression (Hewson et al., 2001; Singer et al., 2001;
Staudinger et al., 2003) on a wide panel of stimulations.
We assessed the permissiveness of differentially activated
macrophages to HIV infection by an ending point titration
method (Fig. 1B), the only strategy which permits assessment of
the real susceptibility to infection without interferences arising
from replication level. IL-4 and the pro-inflammatory molecules
IFN-γ, TNF-α, and LPS decreased the susceptibility to
infection by a factor of at least one log, suggesting the
induction of efficient antiviral activities. TGF-β and PGE2, by
slightly increasing the susceptibility to HIV infection (2- and 5-
fold, respectively), may facilitate cell infection but this effect is
of low magnitude. Other stimulations had almost no effect.
Effect of pro- and anti-inflammatory stimulations on virus
production by macrophages
We assessed macrophage capacity to produce virus over a 4-
week infection period. Cells were stimulated only 3 days before
infection (pre-infection regimen) or stimulated all along the
infection kinetic (long-term regimen). Culture supernatants
were collected twice weekly for RT activity assay. As expected,
the results obtained differed from those of the titration assay
(Fig. 2). M-CSF did not alter cell susceptibility, nor did it
modify replication kinetics. GM-CSF and IL-4 had different
effects on virus apparent titer (Fig. 1B) but led to superimpos-
able replication kinetics (Fig. 2), with a one-passage delay in
virus spread before replication reached the very same levels as
in the controls. The same results were obtained with pre-
infection or long-term M-CSF, GM-CSF and IL-4 treatments.
This is different from the other stimulations tested, where long-
term treatment increased the effect of pre-infection regimen. IL-
10, TGF-β, dexamethasone, and PGE-2, which had nearly no
effect on virus titer (Fig. 1B), were then able to lower the level
of replication with an increased effect of the long-term regimen
(Fig. 2), suggesting a protective activity against virus spread.
TNF-α and LPS lowered virus titer (Fig. 1B), which resulted in
a delayed replication kinetic (Fig. 2). These two molecules
nevertheless could not prevent virus progression in the culture
which finally led to poor inhibition of total HIV production
(<50%) and suggest opposite effects on the early and late steps
of the viral cycle. Finally, only IFN-γ exhibited a strong
antiviral activity: a single pre-treatment allowed a 3-week delay,Fig. 2. Capacity of differentially activated macrophages to produce virus. Effects
of short-term (pre-infection) and long-term (pre- and post-infection) treatments
of the different pro- and anti-inflammatory stimulations on HIV replication in
macrophages. Treatment was initiated 3 days before infection and maintained
throughout culture (long term) or stopped at the time of infection (short term).
Cells were infected on day 0 with HIV-1/Ba-L (MOI = 0.1) and viral replication
was measured regularly by RT activity quantification. Results are expressed as
means ± standard deviations of triplicate well.and HIV replication was completely abolished when IFN-γ was
added all along the culture. Of note, each RT activity value was
normalized on a per cell basis according to the MTT viability
115F. Porcheray et al. / Virology 349 (2006) 112–120assay data. IFN-γ stimulation did not significantly affect cell
viability compared to untreated cells (85% ± 14% at the end of
the kinetic, data not shown).
HIV replication orientates macrophages towards a
pro-inflammatory phenotype
Macrophages secrete cytokines and chemokines which
orchestrate the immune response, and the effect of infection
on macrophage activation is still not clear despite the large
number of studies devoted to this topic (for review, see Fantuzzi
et al., 2003). Indeed HIV infection of macrophages has been
proposed as increasing pro-inflammatory cytokine production,
including IL-1, IL-6, IL-8, and TNF-α but also anti-inflamma-
tory cytokines such as IL-10 (Alfano and Poli, 2002). We
characterized infected macrophage activation phenotypeFig. 3. Consequences of HIV infection on membrane phenotype and cytokine/che
HIV-1/Ba-L (MOI = 0.1) and followed up for 20 days. Framed figure shows the k
the expression level of markers for the alternative activation of macrophages.
expression (left panel) and on β-chemokine production (right panel). (C) Effect of
results are expressed as means ± standard deviations for triplicate. For quantitative
as a percentage of infected to uninfected cells. Shown data are representative ofthrough the quantitative expression of the alternative activation
markers CD163, CD206, CCL18, and IL-10 as well as the pro-
inflammatory cytokines IL-1β, TNF-α, CCL3, CCL4, and
CCL5 (the chemokines MIP-1α, MIP-1β, and RANTES,
respectively). Our data, presented on Fig. 3, show a strong
orientation of macrophage activation phenotype towards a pro-
inflammatory one. Indeed, the expression of CD163, the
hemoglobin/haptoglobin scavenger receptor (Kristiansen et al.,
2001) and CD206, the macrophage mannose receptor, which are
the two main markers for alternative activation, dramatically
decreased when HIV replication occurred and thereafter. CCL18
production, another marker of alternative activation, was also
repressed, while IL-10 production was only modestly lowered
soon after exposure to the virus, in a replication-independent
manner. The effect of HIVon CD4 and CCR5 expression levels
has already been described (Hewson et al., 2001; Karsten et al.,mokine production. Unstimulated macrophages were infected on day 0 with
inetic of HIV replication (RT activity assay). (A) Effect of HIV replication on
(B) Consequences of HIV replication on CD14 and HIV receptor complex
HIV replication on the production of major mediators of inflammation. ELISA
flow cytometry data, the level of expression of surface markers is documented
4 independent experiments.
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in CD4 and CCR5 expression was concomitant with HIV
replication and was not observed at the early step of HIV–cell
contact. These findings suggest either that a minimum level of
viral protein is needed for such down modulation of CD4 and
CCR5, or rather that the inflammatory switch, which also
appears when HIV replicates, plays a role in the regulation of
these receptors. Of note, TNF-α production was not signifi-
cantly modulated throughout the infection kinetic, nor was that
of IL-1β. In addition to the clear pro-inflammatory orientation
of macrophages during infection, the dramatic decrease in CD14
and the scavenger receptors CD163 and CD206 strongly
suggests a mechanism for HIV-induced deficiency in macro-
phage activity as a mediator of innate immunity.
Discussion
The role of inflammation in HIV pathogenesis, particularly
in the CNS, has been investigated by numerous studies (for
review, see De Simone et al., 2004), and the link between
neuronal apoptosis, infection, and inflammation is still a central
issue in understanding the mechanisms that underlie the
development of HIV associated CNS attack. In this study, we
assessed the influence of pro- and anti-inflammatory molecules,
mostly cytokines, on the susceptibility of macrophages to HIV
infection and their capacity to replicate HIV. Previous data have
shown that opposite effects can be exerted by the same stimulus
on different steps of the HIV cycle in macrophages (e.g., TNF-α
(Bailer et al., 2000; Le Naour et al., 1994; Valentin et al., 1992)),
making it difficult to interpret data arising from replication
kinetics. The comparison of results obtained by endpoint
dilution titration (that measures cell susceptibility to effective
infection) with the replication kinetics data (that also integrates
the relative capacity of infected cells to produce virus progeny)
was thus needed to distinguish between early and late infection
step effects. Our data show a partial protection by pro-
inflammatory cytokines and LPS. For example, the minimum
amount of virus needed to infect IFNγ-treated macrophages was
20 times higher than for untreated cells. The anti-inflammatory
cytokine IL-4 also reduced the susceptibility to HIV infection,
suggesting that alternative activation may also provide a partial
protection against HIV infection. Grossly, the expression level
of CD4 and CCR5 correlated well with susceptibility. Our data
further support the finding that CCR5 expression is the critical
factor for HIV entry, as previously published (Ghorpade et al.,
1998; Tuttle et al., 1998; Wu et al., 1997). Of note, the
overexpression of CD4 and CCR5 after IL-10 stimulation did
not affect susceptibility to infection, suggesting that other
parameters may account for virus entry in this case. Also, the
absence of susceptibility modulation by GM-CSF, which
otherwise reduces CCR5 expression to an undetectable level,
is striking. The comparison of virus titer and replication kinetic
shows that the capacity of stimulated macrophages to produce
virus does not overlap with their susceptibility to de novo
infection, underlying the relevance of our titration method.
Some stimulations like M-CSF or GM-CSF had almost no
effect on both susceptibility and virus spread. A stimulatoryeffect of M-CSF on viral replication has been reported (for
review, see Kedzierska et al., 2003), but this is most likely a
consequence of monocyte to macrophage maturation induced
by this growth factor, which also increases HIV-receptors
expressions (Naif et al., 1998; Wang et al., 1998). TNF-α and
LPS lowered the susceptibility without really preventing virus
spread. This illustrates the duality of inflammatory processes
towards HIV, with true antiviral activities that may limit virus
amounts, but also activation and attraction features that provide
new target cells and enhance replication levels. On the contrary,
the anti-inflammatory suppressive molecules IL-10, TGF-β and
dexamethasone, that did not decrease susceptibility to infection,
exhibited an antiviral activity by limiting virus spread, with
more than 80% reduction in the total amount of virus produced.
The inhibitory effect of IL-10 on HIV replication has been
previously reported (Naif et al., 1996; Wang et al., 1998;
Weissman et al., 1994). Although TGF-β and PGE2 slightly
increased MDM susceptibility to infection (Fig. 1B), they
inhibited subsequent viral production to extents comparable to
other stimulations effects (Fig. 2). This biphasic effect is
striking and might be due to CCR-5 competition between HIV
and the chemokines CCL-3, -4, and -5 induced during HIV
replication (Fig. 3C). Indeed, such competition might occur in
the immediate vicinity of chemokine-secreting cells although
the global concentrations obtained in culture supernatant does
not reach inhibitory ones (Capobianchi et al., 1998; Cota et al.,
2000; Kedzierska and Crowe, 2001).
Finally, only IFN-γ exhibited full antiviral properties by
decreasing both susceptibility and virus spread in macrophage
cultures. Several groups have reported the inhibitory effect of IFN-
γ on HIV infection or replication (Denis and Ghadirian, 1994;
Dhawan et al., 1995; Emilie et al., 1992; Fan et al., 1994; Hammer
et al., 1986; Hartshorn et al., 1987; Kornbluth et al., 1989, 1990;
Koyanagi et al., 1988). Some controversies remain in the literature,
but it can be reminded that most of the studies that showed a
positive effect of IFN-γ on HIV replication were not performed
using primary humanmacrophages (Biswas et al., 1992; Han et al.,
1996;Vyakarnam et al., 1990) thatmay explain these discrepancies.
Our data underline the differential regulation of entry/integration
versus expression events and show that all the stimuli tested limit
virus production by macrophages. This suggests that macrophage
activation is rather beneficial as far as virus reservoir capacity is
concerned. Once infected, the influence of macrophages on
inflammation in their vicinity is also an important issue for
understanding the role of macrophages in the inflammatory
syndrome observed during infection. The availability of specific
markers for alternative activation of macrophages provides new
insights for the exploration of (anti) inflammatory settings. The
dramatic decrease observed in both CD163 and CD206 expression
levels in HIV replicating macrophages shows a powerful
orientation towards pro-inflammation. As a control, CD11b levels
on the cell surface remained constant (data not shown). The drop in
CD163 andCD206was concomitantwith theHIVreplication peak,
suggesting that the replication step is critical for this phenotype
switch. Interestingly, this inflammatory orientation was not
dependent on TNF-α or IL-1β, whose levels remained very low.
TNF-α induction by HIV has been abundantly debated during the
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or infection settings. For example, contaminating lymphocytes in
culture or the use of non-ultracentrifuged virus suspensions may
account for such discrepancies.
Although not mediated by the autocrine TNF-α loop, HIV
replicating macrophages adopted a clear pro-inflammatory
phenotype, confirmed by the strong upregulation of CCL3,
CCL4, and CCL5 secretion already described by Choe et al.
(2001). We hypothesized that these changes in cytokine/
chemokine secretion might be the cause of the dramatic
decrease in CD163 and CD206 expression, through autocrine/
paracrine effects. We thus treated uninfected macrophages with
CCL3, CCL4, CCL5, and TNF-α concentrations similar to
those measured in infected cell supernatants. This treatment did
not modulate CD163 and CD206 expression (data not shown).
The mechanism for CD163 and CD206 repression thus remains
to be elucidated. Moreover, the use of these markers may help in
finding new inflammatory pathways, critical for HIV-induced
disease mechanisms, beside the TNF-dependent one.
Nevertheless, the consequences of this phenotype switch
may be deleterious to patients infected with HIV. Indeed, this
pro-inflammatory activation of macrophages participates in the
global immune activation mediated by the virus. The con-
sequences of this general activation on T cell depletion have
been well documented (Grossman et al., 2002; Silvestri and
Feinberg, 2003), and they account mainly for AIDS patho-
genesis. Nevertheless, the actual impact of this macrophage pro-
inflammatory switch during infection on Tcell turnover remains
to be more thoroughly characterized.
In conclusion, our findings provide new insights into the
relationship between macrophages, inflammatory balance, and
HIV. Inflammation/anti-inflammation and the capacity of
macrophages to act as potent HIV reservoirs do not correlate.
Nevertheless, macrophage activation mostly leads to a reduc-
tion in macrophage susceptibility to HIV entry as well as in
macrophage virion progeny, regardless of its orientation
towards either pro- or anti-inflammation. This is in agreement
with the anti-microbial activity of activated macrophages. In
turn, infected macrophages switch to a pro-inflammatory
phenotype, with a high capacity to recruit new target
macrophages through chemokine secretion but probably with
a depressed ability to respond to both external (microorganisms)
and intrinsic (haptoglobin) stimulations. These later data focus
further attention on the macrophage as a vector for HIV spread
and for storage in tissue reservoirs, continually fed with newly
attracted macrophages in the context of a depressed anti-
microbial capacity.
Materials and methods
Human monocyte isolation and differentiation
Monocytes were isolated from healthy seronegative donors
by countercurrent elutriation (Figdor et al., 1983). Monocyte
preparations were more than 95% pure, as assessed by flow
cytometry (data not shown). Monocytes were seeded into
75 cm2 culture flasks in DMEM-glutamax medium (Invitro-gen, San Diego, CA) supplemented with 10% heat inactivated
(+56 °C for 30 min) fetal calf serum (Bio West, Nuaillé,
France) and 1% antibiotic mixture (penicillin–streptomycin–
neomycin 100×, Invitrogen). M-CSF and GM-CSF (10 ng/ml
and 1 ng/ml, respectively, R&D Systems, Minneapolis, MN)
were included in the medium from day 0 to day 6 in order to
improve cell viability. These relative concentrations of
cytokines maintained a neutral environment with respect to
activation marker quantitative expression (HLA-DR, CD163,
CD206), which remained similar to that of MDM cultured
in medium alone (data not shown). Cells were maintained at
37 °C in a humidified atmosphere containing 5% CO2.
Blood monocytes adhered to plastic after 1 h, spontaneously
detached after 48 h and retained a monocyte-like appearance
for 5 days. After 3 days, monocytes were washed with
phosphate-buffered saline (PBS), counted using trypan blue,
and dispensed into 48-well plates (3 × 105 cells/well), except
for the titration assay for which cells were plated in 96-well
plates (105 cells/well), in M-CSF and GM-CSF supplemented
medium. On days 5–6, cells were washed, and fresh medium
was added. Mature macrophages, consisting in morphologi-
cally differentiated macrophages, were obtained by days 7–8.
Cells were then stimulated with pro- or anti-inflammatory
molecules, or infected.
Recombinant cytokines and biologically active substances
Recombinant human M-CSF, GM-CSF, IL-4, IL-10, IFN-γ,
TNF-α were purchased from R&D Systems and used at a
concentration of 10 ng/ml for stimulation. Dexamethasone
(40 ng/ml) was purchased from Qualimed Laboratories (Paris,
France) and PGE2 (10 ng/ml), from Cayman Biochemicals
(Ann Arbor, MI). All substances except for dexamethasone
contained less than 0.1 ng endotoxin per microgram of
product, resulting in endotoxin concentrations of less than
1 pg/ml during the stimulations. Dexamethasone was obtained
from a sterile batch suitable for injection in humans. This
ensured that the observed results did not arise from endotoxin
contamination. LPS (10 ng/ml) was purchased from Sigma
(Saint Louis, MO). We chose to apply these concentrations for
the different stimuli based on those reported in the literature to
activate macrophages (Buechler et al., 2000; Kodelja et al.,
1998; Montaner et al., 1999; Stein et al., 1992; Sulahian et al.,
2000).
Flow cytometric analysis of cell surface molecule expression
Adherent cells were washed with PBS and detached from the
plastic by thorough scraping with a rubber policeman. Non-
specific sites were saturated by incubation at +4 °C with 2%
Tégéline (LFB, Les Ulis, France) in PBS. Cells were then
incubated for 30 min at +4 °C with fluorescein isothiocyanate
(FITC)- or phycoerythrin (PE)-conjugated monoclonal anti-
bodies (mAbs) against CD11b (Immunotech, Marseilles,
France), CD163 (BD Biosciences, Mountain View, CA),
CD206 (BD Biosciences), CD14 (BD Biosciences), CD4 (BD
Biosciences), CCR5 (BD Biosciences), or irrelevant isotype-
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washed twice with cold PBS, fixed in 200 μl CellFix (BD
Biosciences), and their fluorescence was assessed with a LSR
flow cytometer (BD Biosciences). Viable cells were gated
according to forward and side light-scatter patterns. The mean
equivalent fluorochrome bound per cell (MEF) was determined
with the DAKO Fluorosphere kit (Dako, Glostrup, Denmark).
This made it possible to eliminate variation due to cytometer
settings and day-to-day performance variability, as well as
differences in stimulation dependent autofluorescence levels.
Viability assay
Stimulated cell viability was measured by the MTT assay
(Sigma). Briefly, cells were washed twice in PBS and incubated
in the presence of 50 μl of MTT solution (5 mg/ml) for 2 h at
37 °C. We then added 0.3 ml of extraction buffer (8% HCl in
isopropanol). The solution was transferred to a 96-well plate,
and optical density was measured at 540–630 nm. The OD of
blank wells (lacking cells, but manipulated in the same way)
were subtracted from the values obtained for the test wells. We
checked that MTT results were representative of the number of
viable cells by counting the number of cells in five microscope
fields per well, by trypan blue exclusion. The results obtained
were similar to those obtained with the MTT assay (data not
shown). We therefore used the MTT assay in subsequent
experiments to normalize data to a fixed number of cells. MTT
assays were performed for every treatment on two additional
replicates and in the very same cells as the triplicate wells that
were used for marker assessment.
Viruses, infection, and quantification of HIV-1 replication
We used the macrophage-tropic HIV-1 reference strain Ba-L
(Gartner et al., 1986). This virus was amplified in vitro using
only human PHA-P-activated umbilical blood mononuclear
cells (UBMC). Clarified cell-free UBMC culture supernatants
were ultracentrifuged at 360,000 g for 10 min at 4 °C just prior
to virus use, to eliminate soluble factors such as cytokines and
avoid non-specific modulations. MDM were infected at a
multiplicity of infection (MOI) of 0.1 at days 7–8 of culture. At
day 1 post-infection, cells were thoroughly washed to remove
residual virus. Supernatant was collected twice weekly until day
25 p.i. and stored at −20 °C to measure RT activity using a
commercial kit (RetroSys®, Innovagen, Lund, Sweden). RT
activity values were corrected according to the results of an
MTT assay to normalize data with respect to untreated cell
number.
Susceptibility to HIV infection
Susceptibility to productive infection was assessed by an
endpoint dilution titration method. Macrophages were stimu-
lated by different molecules for 3 days. Differentially stimulated
macrophages were then infected with 9 sequential threefold
HIV-1/Ba-L dilutions, starting at a MOI of 0.1 as titrated on
control PBMCs, in five replicate wells. 24 h after infection, cellswere extensively washed to remove excess virus and cultured in
200 μl of DMEM per well. Medium was replaced twice a week.
Supernatants were assessed for RT activity with a commercial
kit (RetroSys kit; Innovagen, Lund, Sweden) over a 4-week
period to ensure detection of every productive infection event.
Virus titer was calculated using the Karber's formula (Karber,
1931). This method only takes into account the frequency of
positive wells at each virus dilution and calculates the apparent
titer of the viral suspension, i.e., the minimal quantity of virus
necessary to productively infect 50% of replicate wells. This
titer value depends both on the viral suspension used, which is
always the same in our experiments, and on the cell
susceptibility to infection, which may here vary according to
activation events.
Cytokine determination
Commercially available ELISA kits were used to determine
the concentration of IL-8, IL-10, IL-1β, CCL2, CCL3, CCL4,
and CCL5 (R&D Systems). CCL18 ELISA was performed
using a specific antibody pair, according to the manufacturer's
instructions (R&D Systems). To eliminate variation due to
differences in viability, concentrations were expressed with
respect to the number of untreated cells, according to the MTT
results, as follows: normalized pg/ml = measured pg/ml × (control
cells MTT OD/treated cells MTT OD). Cytokine content was
measured in supernatants harvested 24 h after culture passage
and addition of fresh stimulation medium.
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